Brutalist Biotech
Max
3
|
5
|
10
|
20
items per feed.
Cutting-edge Biotech news: Presented the old-fashioned way.
Fierce Biotech
Clario acquires WCG's neuroscience-focused clinical outcome assessment business
(1d)
Insilico Medicine raises $110M for new trials and robotic helping hands
(1d)
J&J’s Monarch bronchoscopy robot cleared by FDA to connect to live CT scans
(1d)
Manufacturer fuels Swiss biotech’s next-gen vaccine portfolio in new investment deal
(1d)
GSK posts data on HIV assets vying for roles in 6-month combo
(1d)
BioPharma Dive
MeiraGTx spins Parkinson’s, obesity gene therapies into AI startup
(4h)
Mallinckrodt, Endo to combine in $7B deal
(5h)
Roche broadens obesity drug plans with $1.65B Zealand deal
(1d)
A new obesity biotech launches; Gilead plans to quickly advance once-yearly PrEP for HIV
(1d)
Flagship startup raises $200M in pursuit of ‘scientific superintelligence’
(1d)
Endpoints News*
MeiraGTx partners with cryptic AI startup Hologen to advance Parkinson's gene therapy
(4h)
With Hinge Health filing to go public, are we... back?
(4h)
Acelyrin, Pliant turn to ‘poison pill’ as Kevin Tang’s Concentra pursues both companies
(5h)
Canada pitches in to Entos' facility build; Vetter expands in Germany
(5h)
White House pulls Weldon's nomination to lead CDC
(7h)
BioSpace
Trump Administration Pulls CDC Nominee Dave Weldon at Last Minute
(5h)
Houston’s Life Sciences Scene Continues Boosting Its Reputation
(5h)
Acelyrin Adopts Poison Pill to Ward Off Tang Capital Buy
(6h)
“Perfect Patient” Industry Burdens; Exits and Investment in Women’s Health
(6h)
Amgen's Uplizna Deepens Response Against Myasthenia Gravis at 1 Year
(6h)
Stat News*
Study reveals how often medical device makers report safety incidents late to FDA
(4h)
Trump’s picks to run FDA and NIH win approval from Senate’s health committee
(6h)
A study on brains and a statement on driving
(6h)
Pharmalittle: We’re reading about senators probing telehealth, Boston’s slumping biotech hub and more
(6h)
White House pulls nomination of Dave Weldon as CDC director hours before hearing
(7h)
BioPharma Trend
Elsevier Launches ScienceDirect AI to Provide Summarized Research Insights
(4h)
Elsevier Launches AI to Provide Summarized Research Insights
(7h)
Tempus Acquires AI-Powered Clinical Trial Matching Platform
(8h)
Insilico Medicine Raises $110M to Advance AI Drug Design, Unveils its Humanoid Lab Robot
(1d)
Lila Sciences Raises $200M to Automate Scientific Discovery with AI and Robotics
(2d)
Labiotech.EU
Nine biotechs thriving in Seattle in 2025
(6h)
Checkpoint inhibitors in cancer: breakthroughs, setbacks, and what’s next
(1d)
The gender gap in clinical trials: Why women are still underrepresented
(2d)
23andMe: the collapse of a genomics giant
(3d)
Catalonia: A biotech hub going from strength to strength, with Barcelona at its core
(6d)
GEN News
Mallinckrodt, Endo Plan $6.7B Merger
(1h)
Structure of Key Parkinson’s Disease Protein, PINK1, Seen for First Time
(2h)
Batavia Biosciences Partners with VBC and MEVAC to Advance Localized Vaccine Manufacturing in Egypt
(2h)
DNA Nanostructures That Form Without Extreme Heat Could Boost Drug Delivery, Diagnostics
(17h)
Extrachromosomal DNA Carrying MYC Drives Pancreatic Cancer Aggression
(19h)
Cure Today
Dr. Kevin Kalinsky Covers Targeted Therapy in HER2– Breast Cancer
(1h)
Trusting My Stage 4 Breast Cancer Body
(3h)
ctDNA Testing May Offer Patients With RCC ‘Peace of Mind’
(4h)
First Patient Dosed With Recombinant Bacillus Calmette-Guérin in Bladder Cancer
(5h)
Xtandi and Talzenna Therapy Shows Responses in Advanced Prostate Cancer
(7h)
Contract Pharma*
What’s New: Business Updates from Across the OSD Sector
(4h)
Batavia Biosciences Partners with VBC & MEVAC to Enhance Vaccine Manufacturing Capabilities in Egypt
(4h)
Mallinckrodt and Endo Agree to Combine
(5h)
Coronado Research Appoints Nick Littlebury as EVP of Regulatory Affairs
(5h)
Bristol Meyers Squibb to Acquire 2seventy bio
(5h)
The Pharma Letter*
Gene therapy for Parkinson’s at heart of new AI collab
(57m)
Troubled Mallinckrodt and Endo to merge
(3h)
Salipro Biotech inks deal with Boehringer
(3h)
Sareum sees future for cancer asset
(4h)
SOTIO takes up option on Synaffix ADCs
(5h)
Targeted Oncology
Experts Discuss Tislelizumab’s FDA Approval in Esophageal Cancer
(1h)
Dr. Galsky’s Perspectives on the CheckMate 274 Data Results
(2h)
Clinical Perspectives for the Treatment of R/M NPC
(2h)
Phase 3 CheckMate 274 Study: Adjuvant Nivolumab for High-Risk MIUC—Updated Results
(2h)
Treatment Paradigms in R/M NPC: The Role of Systemic Immunotherapy
(2h)
MedWatch*
AJ Vaccines' bylaws block CEO's wish for women on the board
(5h)
Genmab re-elects board of directors at AGM
(6h)
Eli Lilly chief's salary surged to USD 29.2m in 2024
(6h)
US drug compounders challenge FDA decision to remove obesogens from shortage list
(7h)
Trade association for compounded drugs oppose FDA removal of obesogens from shortage list
(7h)
In The Pipeline
Crystallization Cages
(2h)
A Bifunctional Degrader Reads Out in Phase 3
(1d)
New Synthetic Antibiotics
(2d)
Single-Base Editing Seems to Work
(3d)
Bird is the (Geomagnetic) Word
(6d)
Pharmaphorum
Trump pulls CDC head nomination as FDA, CDC picks advance
(5h)
Insilico raises $110m for AI-designed drug pipeline
(6h)
'Transformational' pill for endometriosis gets NHS nod
(7h)
UK PM Keir Starmer reveals plan to abolish NHS England
(8h)
Is Mallinckrodt about to merge with Endo?
(9h)
Drug Discovery Weekly
First patient dosed in gene therapy study for Stargardt disease
(3h)
New podcast: The revolutionary impact of understanding genomics
(5h)
The revolutionary impact of understanding genomics
(5h)
BMS buys CAR-T company 2seventy bio
(7h)
First clinical genetic correction of a disease-causing mutation reported
(9h)
Reddit Biotech
Curve therapeutics
(12h)
Hot take
(12h)
Advice on moving into clinical roles
(16h)
Seeking Advice on Transitioning into Biotech with a Non-Traditional Background
(17h)
In squid game season 2 Gi hun removes a tracking chip from behind his ear. Is that a realistic location for such a device?
(18h)
Google News Biotech
George Church spinout GRObio explores strategic alternatives 6 months after Bayer-backed series B - Fierce Biotech
(2h)
Salipro Biotech inks deal with Boehringer
(3h)
Biotech Alert: Searches spiking for these stocks today - TipRanks
(3h)
VUB to strengthen Brussels' position in biotech sector - The Brussels Times
(4h)
Sotio takes up option on ADCs, Boehringer inks discovery pact - Fierce Biotech
(5h)
* May require subscription